The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 21, 2025
Filed:
May. 19, 2017
Applicant:
The General Hospital Corporation, Boston, MA (US);
Inventors:
Youssef Jounaidi, Boston, MA (US);
Stuart Forman, Arlington, MA (US);
Keith Miller, Lincoln, MA (US);
Joseph F. Cotten, Northborough, MA (US);
Assignee:
The General Hospital Corporation, Boston, MA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/46 (2006.01); A61K 39/00 (2006.01); C07K 14/55 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); C07K 19/00 (2006.01); C12N 5/00 (2006.01); C12N 5/0783 (2010.01); C12N 15/00 (2006.01); A61K 9/00 (2006.01); A61K 38/00 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
C07K 14/55 (2013.01); A61K 39/4613 (2023.05); A61K 39/464406 (2023.05); A61K 39/464493 (2023.05); C07K 14/70521 (2013.01); C07K 14/7155 (2013.01); C12N 5/0646 (2013.01); A61K 9/0019 (2013.01); A61K 38/00 (2013.01); A61K 45/06 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); A61K 2239/47 (2023.05); A61K 2239/58 (2023.05); C07K 2319/33 (2013.01); C12N 2510/00 (2013.01);
Abstract
Fusion proteins comprising IL2 and IL2Rβ (e.g., CIRB), IL2, IL2Rβ and IL21R (e.g., CIRB21), and/or comprising IL2, IL2Rβ, and CD28 (e.g., CIRB28); natural killer (NK) cells that express the fusion proteins and methods of use thereof, e.g., to treat subjects with cancer; and regulatory T cells (T-regs) that express a fusion protein comprising IL2, IL2Rβ, and CD28 and methods of use thereof, e.g., to treat subjects with autoimmune disease or GVHD.